Pages that link to "Q27851588"
Jump to navigation
Jump to search
The following pages link to Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer (Q27851588):
Displaying 50 items.
- Evolutionary dynamics of cancer in response to targeted combination therapy (Q21128788) (← links)
- Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma (Q21285042) (← links)
- Initial impact of the sequencing of the human genome (Q22122172) (← links)
- Cancer genome landscapes (Q22242276) (← links)
- Third-line systemic treatment for non-small cell lung cancer (Q24194090) (← links)
- Design and Analysis for Studying microRNAs in Human Disease: A Primer on -Omic Technologies (Q24289207) (← links)
- MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling (Q24304423) (← links)
- ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma (Q24310296) (← links)
- Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies - Past, Present, and Future (Q24564024) (← links)
- Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene (Q24598210) (← links)
- Epidemiology of lung cancer (Q24600475) (← links)
- Genetic Heterogeneity and Clonal Evolution of Tumor Cells and their Impact on Precision Cancer Medicine (Q24604479) (← links)
- Crizotinib: A comprehensive review (Q24624083) (← links)
- Clinical use of crizotinib for the treatment of non-small cell lung cancer (Q24630466) (← links)
- Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations (Q24632064) (← links)
- Crizotinib resistance: implications for therapeutic strategies (Q26738381) (← links)
- The role of the ALK receptor in cancer biology (Q26738384) (← links)
- Crizotinib: from discovery to accelerated development to front-line treatment (Q26738385) (← links)
- ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology (Q26738387) (← links)
- Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection (Q26738860) (← links)
- Targeted therapies and immunotherapy in non-small-cell lung cancer (Q26738986) (← links)
- Tackling ALK in non-small cell lung cancer: the role of novel inhibitors (Q26740329) (← links)
- Non-small cell lung cancer: current treatment and future advances (Q26740333) (← links)
- Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives (Q26741009) (← links)
- Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications (Q26741318) (← links)
- Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand? (Q26741814) (← links)
- Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far (Q26745776) (← links)
- New treatment options for ALK advanced non-small-cell lung cancer: critical appraisal of ceritinib (Q26746230) (← links)
- Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC (Q26747276) (← links)
- Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine (Q26748603) (← links)
- Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients (Q26750428) (← links)
- Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomas (Q26752945) (← links)
- Targeting hypoxic response for cancer therapy (Q26767351) (← links)
- Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities (Q26768158) (← links)
- Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs (Q26769659) (← links)
- ALK inhibitors in non-small cell lung cancer: the latest evidence and developments (Q26769879) (← links)
- Role of FNAC, fluid specimens, and cell blocks for cytological diagnosis of lung cancer in the present era (Q26774726) (← links)
- ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance (Q26775347) (← links)
- New strategies in immunotherapy for non-small cell lung cancer (Q26775385) (← links)
- Lung cancer biomarkers, targeted therapies and clinical assays (Q26775396) (← links)
- Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib (Q26775817) (← links)
- Leveraging big data to transform target selection and drug discovery (Q26776403) (← links)
- Translating cancer genomes and transcriptomes for precision oncology (Q26777081) (← links)
- Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer (Q26778500) (← links)
- Precision medicine for cancer with next-generation functional diagnostics (Q26780232) (← links)
- The distinctive nature of adenocarcinoma of the lung (Q26781159) (← links)
- Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development (Q26783932) (← links)
- Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis (Q26784085) (← links)
- Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions (Q26784113) (← links)
- Patterns of Chromosomal Aberrations in Solid Tumors (Q26786127) (← links)